ʻO Curebase, kahi hui i kūpaʻa i ka democratizing i ke komo ʻana i nā noiʻi lāʻau lapaʻau, a me Blue Note Therapeutics, kahi hui prescription digital therapeutics (PDT) i hoʻolaʻa ʻia no ka hoʻēmi ʻana i ke kaumaha o ka maʻi kanesa a me ka hoʻomaikaʻi ʻana i nā hopena, ua hoʻolaha i ka hui pū ʻana i kahi hoʻokolohua hoʻokolohua virtual e aʻo ai i ka pono. o ʻelua lāʻau lapaʻau kikohoʻe. Manaʻo ʻia nā therapeutic digital ʻelua i ka hopena i ke olakino noʻonoʻo a me ke kino ke hoʻohana pū ʻia me nā regimens mālama oncology multidisciplinary.

ʻO ka pahuhopu o ka hoʻāʻo ʻana me Curebase ʻo ia ka hoʻonui ʻana i kā mākou hoʻoikaika ʻana me nā poʻe maʻi e loaʻa ana i ka pilikia pili i ka maʻi kanesa a loaʻa paha ka pōmaikaʻi mai kahi hoʻāʻo virtual piha, me nā kumuhana home ʻaʻole hiki a makemake ʻole e hele i kahi hoʻokolokolo. paena. ʻO kēia ka mea e hiki ai iā Blue Note ke komo i ka poʻe maʻi i hōʻike ʻole ʻia ma nā haʻawina lapaʻau maʻamau. Hiki ke aʻo hou aku i ka poʻe me ka maʻi kanesa a me ka hoihoi i kēia hoʻokolohua virtual.

E hoʻohana ʻia ke kahua hoʻāʻo hoʻokolohua hoʻonaʻauao ʻo Curebase (DCT) no ka hoʻopaʻa ʻana i nā mea komo, ka pale, ka ʻae, a laila kōkua i ke alakaʻi ʻana iā lākou ma o ka hōʻike ʻana a me nā hana i koi ʻia no ke aʻo ʻana. E hoʻohana ʻo Curebase i kāna mau hana pūnaewele virtual a me ka hoʻokele haʻawina e hoʻokō ai i ke aʻo ʻana. Ke kiʻi nei ʻo Blue Note i nā mea maʻi 353 no ka hoʻokolokolo mamao loa, e hoʻomaka ana i ka hoʻomaka o Malaki. Manaʻo ʻia ka ʻikepili mai kēia hoʻāʻo ʻana e kākoʻo i ka hoʻouna ʻana o ka hoʻoponopono hoʻoponopono o Blue Note Therapeutics i ka US Food and Drug Administration.

"ʻIke pinepine nā poʻe maʻi e noho nei me ka maʻi kanesa i ke kaumaha, ka hopohopo, a me ke kaumaha. No nā mea he nui, ua piʻi aʻe kēia mau hōʻailona i ka wā maʻi maʻi COVID-19 me nā mea mālama olakino a me nā pilikia i ka mālama maʻi kanesa, "wahi a Geoffrey Eich, Luna Nui, Blue Note Therapeutics. "ʻO kā mākou hui pū ʻana me Curebase he mea hauʻoli ia i ka hui pū ʻana i kā mākou mau mana kūʻokoʻa e hoʻonui i kā mākou hiki i ka hoʻopaʻa ʻana no kēia hoʻokolohua lapaʻau piha piha. Ke hoʻohana nei i ka ʻenehana hou loa, hiki iā mākou ke hāʻawi i nā mea maʻi i kahi ala kūpono e komo ai a me ka mea a mākou e manaʻo ai e hoʻomaikaʻi ʻia ke olakino kino a me ka noʻonoʻo.

ʻO ke kumu hoʻohālike DCT o Curebase e hōʻoiaʻiʻo i nā haʻawina like ʻole no ka mea hiki ke hoʻokomo ʻia nā heluna kūʻokoʻa - ka mea maʻamau i hōʻike ʻole ʻia i nā hoʻokolohua lapaʻau. Hāʻawi pū nā pūnaewele noiʻi virtual o ka hui i nā kauka i nā koho hou a kūʻokoʻa e hāʻawi i kā lākou poʻe maʻi, me ka ʻole o ka wahi.

"ʻO ka poʻe i ʻike ʻia me ka maʻi kanesa ʻaʻole wale lākou e hana i kēia maʻi ma kahi pae kino, paʻakikī pinepine lākou me ke kaumaha a me nā ʻano manaʻo maikaʻi ʻole," wahi a Tom Lemberg, Luna Nui a hoʻokumu, Curebase. "Ke manaʻolana nei mākou e hōʻike ana kēia hoʻāʻo ʻana e hiki i ka poʻe me ka maʻi kanesa ke hoʻomaha maikaʻi i ko lākou kaumaha i loko o ka ʻoluʻolu a me ka ʻoluʻolu o ko lākou mau home ponoʻī."

He aha e lawe ʻia mai kēia ʻatikala:

Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, have announced a collaboration on a virtual clinical trial that will study the effectiveness of two digital therapeutics.
The goal of the joint trial with Curebase is to maximize our recruitment efforts with patients experiencing cancer-related distress and who may benefit from a fully virtual trial, including home-based subjects who can’t or wouldn’t want to travel to a trial site.
Using the latest in digital technology, we’re now able to offer patients a convenient way to participate and what we hope will be improved physical and mental health.